Tectorigenin protects against cardiac fibrosis in diabetic mice heart via activating the adiponectin receptor 1-mediated AMPK pathway - 27/04/24
Abstract |
Diabetic cardiomyopathy (DCM) is a common severe complication of diabetes that occurs independently of hypertension, coronary artery disease, and valvular cardiomyopathy, eventually leading to heart failure. Previous studies have reported that Tectorigenin (TEC) possesses extensive anti-inflammatory and anti-oxidative stress properties. In this present study, the impact of TEC on diabetic cardiomyopathy was examined. The model of DCM in mice was established with the combination of a high-fat diet and STZ treatment. Remarkably, TEC treatment significantly attenuated cardiac fibrosis and improved cardiac dysfunction. Concurrently, TEC was also found to mitigate hyperglycemia and hyperlipidemia in the DCM mouse. At the molecular level, TEC is involved in the activation of AMPK, both in vitro and in vivo, by enhancing its phosphorylation. This is achieved through the regulation of endothelial-mesenchymal transition via the AMPK/TGFβ/Smad3 pathway. Furthermore, it was demonstrated that the level of ubiquitination of the adiponectin receptor 1 (AdipoR1) protein is associated with TEC-mediated improvement of cardiac dysfunction in DCM mice. Notably the substantial reduction of myocardial fibrosis. In conclusion, TEC improves cardiac fibrosis in DCM mice by modulating the AdipoR1/AMPK signaling pathway. These findings suggest that TEC could be an effective therapeutic agent for the treatment of diabetic cardiomyopathy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Tectorigenin(TEC) ameliorates myocardial fibrosis and improves cardiac dysfunction in DCM. |
• | TEC alleviates endothelial-to-mesenchymal transition (EndMT) and fibroblast proliferation in DCM. |
• | TEC Augments the Phosphorylation Levels of AMPK via Enhancing AdipoR1 Expression in DCM. |
• | TEC attenuates cardiac dysfunction by regulating ubiquitinated degradation of AdipoR1 in DCM. |
Keywords : Tectorigenin, Diabetic cardiomyopathy, Cardiac fibrosis, AdipoR1, AMPK
Plan
Vol 174
Article 116589- mai 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?